Cardioprotection by selective SGLT-2 inhibitors in a non-diabetic mouse model of myocardial ischemia/reperfusion injury: a class or a drug effect?-Reference-Cited by-同舟云学术

Cardioprotection by selective SGLT-2 inhibitors in a non-diabetic mouse model of myocardial ischemia/reperfusion injury: a class or a drug effect?

Published:2022-05-17 Issue:1 Volume:117 Page:
ISSN:0300-8428
Container-title:Basic Research in Cardiology
language:en
Short-container-title:Basic Res Cardiol

Author:

Nikolaou Panagiota Efstathia,Mylonas Nikolaos,Makridakis Manousos,Makrecka-Kuka Marina,Iliou Aikaterini,Zerikiotis Stelios,Efentakis Panagiotis,Kampoukos Stavros,Kostomitsopoulos Nikolaos,Vilskersts Reinis,Ikonomidis Ignatios,Lambadiari Vaia,Zuurbier Coert J.,Latosinska Agnieszka,Vlahou Antonia,Dimitriadis George,Iliodromitis Efstathios K.,Andreadou Ioanna^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Physiology (medical),Cardiology and Cardiovascular Medicine,Physiology

Link

https://link.springer.com/content/pdf/10.1007/s00395-022-00934-7.pdf

Reference102 articles.

1. Al-Jobori H, Daniele G, Cersosimo E, Triplitt C, Mehta R, Norton L, DeFronzo RA, Abdul-Ghani M (2017) Empagliflozin and kinetics of renal glucose transport in healthy individuals and individuals with type 2 diabetes. Diabetes 66:1999–2006. https://doi.org/10.2337/db17-0100

2. Amin EF, Rifaai RA, Abdel-Latif RG (2020) Empagliflozin attenuates transient cerebral ischemia/reperfusion injury in hyperglycemic rats via repressing oxidative-inflammatory-apoptotic pathway. Fundam Clin Pharmacol 34:548–558. https://doi.org/10.1111/fcp.12548

3. Andreadou I, Bell RM, Bøtker HE, Zuurbier CJ (2020) SGLT2 inhibitors reduce infarct size in reperfused ischemic heart and improve cardiac function during ischemic episodes in preclinical models. Biochim Biophys Acta Mol Basis Dis. https://doi.org/10.1016/j.bbadis.2020.165770

4. Andreadou I, Cabrera-Fuentes HA, Devaux Y, Frangogiannis NG, Frantz S, Guzik T, Liehn EA, Gomes CPC, Schulz R, Hausenloy DJ (2019) Immune cells as targets for cardioprotection: new players and novel therapeutic opportunities. Cardiovasc Res 115:1117–1130. https://doi.org/10.1093/cvr/cvz050

5. Andreadou I, Efentakis P, Balafas E, Togliatto G, Davos CH, Varela A, Dimitriou CA, Nikolaou P-E, Maratou E, Lambadiari V, Ikonomidis I, Kostomitsopoulos N, Brizzi MF, Dimitriadis G, Iliodromitis EK (2017) Empagliflozin limits myocardial infarction in vivo and cell death in vitro: role of STAT3, mitochondria, and redox aspects. Front Physiol 8:1077. https://doi.org/10.3389/fphys.2017.01077

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cardioprotection of Canagliflozin, Dapagliflozin, and Empagliflozin: Lessons from preclinical studies;Chemico-Biological Interactions;2024-11

2. Cardioprotective potential of oleuropein, hydroxytyrosol, oleocanthal and their combination: Unravelling complementary effects on acute myocardial infarction and metabolic syndrome;Redox Biology;2024-10

3. SGLT2 inhibitors: how do they affect the cardiac cells;Molecular and Cellular Biochemistry;2024-08-19

4. SGLT1 contributes to glucose-mediated exacerbation of ischemia–reperfusion injury in ex vivo rat heart;Basic Research in Cardiology;2024-08-01

5. Empagliflozin in Acute Myocardial Infarction Reduces No-Reflow and Preserves Cardiac Function by Preventing Endothelial Damage;JACC: Basic to Translational Science;2024-08